The newly allowed U.S. patents focus on 2-bromolysergic acid diethylamide hydrobromide, the specific salt form Ceruvia intends to bring to market. By securing rights to both this crystalline structure and high-purity manufacturing methods—including routes derived from bromocriptine—the company aims to ensure formulation stability and long-term shelf life. This intellectual property portfolio is expected to provide coverage through 2042, potentially offering the company a pathway for FDA Orange Book listing and regulatory patent-term extensions.

Carey Turnbull, founder and CEO of Ceruvia, emphasized that the transition from a known scientific molecule to a commercial pharmaceutical requires rigorous development. The company’s research, conducted alongside partners like Curia, resulted in a non-hygroscopic material designed for scalable production. With $8 million in fresh funding, Ceruvia is preparing to launch an integrated Phase 1/2 clinical program. The company plans to submit a Clinical Trial Application in Germany this September, targeting the first patient enrollment by the end of 2026.